Plus   Neg

Staples CEO Ronald Sargent's 2014 Total Compensation Up 15% To $12.39 Mln

Office supplies retailer Staples Inc. (SPLS) disclosed in a regulatory filing that its Chief Executive officer Ronald Sargent received a 2014 total compensation that was about 15 percent higher than the prior year, while his base salary remained unchanged in 2014 as well as 2013.

The increase in total compensation for its CEO in 2014 from 2013 was primarily due to the payment in 2014 of an annual cash incentive award earned under the Amended and Restated Executive Officer Incentive Plan. No annual cash incentive award was earned in 2013. The increase in total compensation for its CEO in 2013 and 2014 as compared to 2012 was primarily related to a change in the form of incentive awards granted to its NEOs.

Sargent received a total compensation of $12.39 million, including base salary, stock grants and incentives in 2014, compared to the $10.77 million he received in 2013, and $6.47 million he got in 2012.

The total compensation received by Sargent in 2014 includes $1.25 million as base salary, $8.23 million as stock grants, and non-equity incentive plan compensation of $2.59 million.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT